Guardant Health, Inc. Common Stock (GH) is a publicly traded Healthcare sector company. As of May 20, 2026, GH trades at $112.54 with a market cap of $12.68B and a P/E ratio of -33.50. GH moved +17.08% today. Year to date, GH is +12.86%; over the trailing twelve months it is +187.64%. Its 52-week range spans $20.14 to $120.74. Analyst consensus is strong buy with an average price target of $128.88. Rallies surfaces GH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Guardant Health Q1 Revenue Rises 48% to $301.7M, Raises 2026 Guidance: Guardant Health reported first-quarter revenue of $301.7 million, up 48% year-on-year, driven by oncology revenue of $205.0 million (+36%) on approximately 86,000 tests (+47%). The company also raised its full-year 2026 revenue guidance.
| Metric | Value |
|---|---|
| Price | $112.54 |
| Market Cap | $12.68B |
| P/E Ratio | -33.50 |
| EPS | $-3.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $120.74 |
| 52-Week Low | $20.14 |
| Volume | 4.14M |
| Avg Volume | 0 |
| Revenue (TTM) | $982.02M |
| Net Income | $-416.28M |
| Gross Margin | 64.46% |
19 analysts cover GH: 0 strong buy, 18 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $128.88.